EuroBiotech: More Articles of Note

(NS Newsflash/CC BY 2.0)

> Scancell raised £7.5 million ($10.7 million) to start a phase 2 trial of its cancer vaccine in combination with a checkpoint inhibitor. Statement

> Innate Pharma posted preliminary data on NKG2A monoclonal antibody monalizumab in combination with Erbitux. Eight of the 26 evaluable squamous cell carcinoma of the head and neck patients had partial responses. Release

> Autolus shared early data on its anti-GD2 CAR-T therapy. Statement


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> BioCanCell raised $22.8 million to take its bladder cancer candidate into a pivotal trial. Release

> Adocia began a first-in-human trial of its pramlintide-human insulin fixed dose combination. Statement

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.